T
Timothy R. Sterling
Researcher at Vanderbilt University
Publications - 329
Citations - 18933
Timothy R. Sterling is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Tuberculosis & Cohort. The author has an hindex of 61, co-authored 294 publications receiving 15893 citations. Previous affiliations of Timothy R. Sterling include Oklahoma State University Center for Health Sciences & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Hasina Samji,Angela Cescon,Robert S. Hogg,Robert S. Hogg,Sharada P. Modur,Keri N. Althoff,Kate Buchacz,Ann N. Burchell,Mardge H. Cohen,Kelly A. Gebo,M. John Gill,Amy C. Justice,Gregory D. Kirk,Marina B. Klein,P. Todd Korthuis,Jeffrey N. Martin,Sonia Napravnik,Sean B. Rourke,Timothy R. Sterling,Michael J. Silverberg,Stephen G. Deeks,Lisa P. Jacobson,Ronald J. Bosch,Mari M. Kitahata,James J. Goedert,Richard D. Moore,Stephen J. Gange +26 more
TL;DR: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.
Journal ArticleDOI
An official ATS statement: hepatotoxicity of antituberculosis therapy.
Jussi J. Saukkonen,David L. Cohn,Robert M. Jasmer,Steven Schenker,John A. Jereb,Charles M. Nolan,Charles A. Peloquin,Fred M. Gordin,David Nunes,Dorothy B. Strader,John Bernardo,Raman Venkataramanan,Timothy R. Sterling +12 more
TL;DR: Systematic steps for prevention and management of TB DILI are recommended, including patient and regimen selection to optimize benefits over risks, effective staff and patient education, ready access to care for patients, good communication among providers, and judicious use of clinical and biochemical monitoring.
Journal ArticleDOI
The emergence of drug-resistant tuberculosis in New York City.
Thomas R. Frieden,Timothy R. Sterling,Ariel Pablos-Mendez,James O. Kilburn,George M. Cauthen,Samuel W. Dooley +5 more
TL;DR: There has been a marked increase in drug-resistant tuberculosis in New York City and previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance.
Journal ArticleDOI
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Adam Trickey,Margaret T May,Jorg-Janne Vehreschild,Niels Obel,M. John Gill,M. John Gill,Heidi M. Crane,Christoph Boesecke,Sophie Patterson,Sophie Grabar,Charles Cazanave,Matthias Cavassini,Leah Shepherd,Antonella d'Arminio Monforte,Ard van Sighem,Michael S. Saag,Fiona C Lampe,Vicky Hernando,Marta Montero,Robert Zangerle,Amy C. Justice,Timothy R. Sterling,Timothy R. Sterling,Suzanne M Ingle,Jonathan A C Sterne +24 more
TL;DR: Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity.